drugset / Trial / NCT02183012

Study to Investigate the Relative Bioavailability of Ibuprofen in Healthy Volunteers

NCT02183012

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

* Study to demonstrate average bioequivalence between a 400 mg ibuprofen extrudate tablet (Test) and a 400 mg ibuprofen lysinate tablet (Dolormin extra ®; reference 1) under fasted conditions. * Study to determine the relative bioavailability of ibuprofen following single administration of a 400 mg ibuprofen extrudate tablet (Test) compared to a 400 mg ibuprofen tablet (Brufen® 400mg, Denmark; Reference 2) under fasted conditions. * Study to determine the relative bioavailability of ibuprofen following single administration of a 400 mg ibuprofen extrudate tablet (Test) compared to a 400 mg ibuprofen lysinate tablet (Dolormin extra ®; reference 1) or a 400 mg ibuprofen tablet (Brufen® 400mg, Denmark; Reference 2), respectively, under fed conditions. * Study to evaluate the effect of food on the pharmacokinetics of ibuprofen for all three formulations.

Timeline

Start
2002-08
Primary completion
2002-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ibuprofen Small molecule 400 mg

Indications

No indication recorded.